These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11850170)

  • 1. Use of Etests with carbapenems for Gram-negative rods producing beta-lactamases.
    Kocazeybek BS; Arabaci U
    Int J Antimicrob Agents; 2002 Feb; 19(2):159-62. PubMed ID: 11850170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [in vitro activity of carbapenems against Enterobacteriaceae and Pseudomonas aeruginosa hyperproducers of group 1 chromosomal beta-lactamases].
    Martínez-Beltrán J; Calderón C; Sierra MP; Alvarez M; Cantón R
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():20-6. PubMed ID: 9410065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
    Chanal C; Sirot D; Chanal M; Cluzel M; Sirot J; Cluzel R
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():133-41. PubMed ID: 2808205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metallo-beta-lactamase-producing gram-negative rods isolated from inpatients and outpatients, detected using Etest MBL].
    Rokosz A; Sawicka-Grzelak A; Luczak M
    Med Dosw Mikrobiol; 2006; 58(1):73-81. PubMed ID: 16871976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.
    Bedenic B; Goic-Barisic I; Budimir A; Tonkic M; Mihajkevic LJ; Novak A; Sviben M; Plecko V; Punda-Polic V; Kalenic S
    J Chemother; 2010 Jun; 22(3):147-52. PubMed ID: 20566417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases.
    Sanders CC; Sanders WE; Thomson KS; Iaconis JP
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():187-96. PubMed ID: 2808207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
    Mushtaq S; Vickers A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Participation of metallo-beta-lactamases in resistance to imipenem and meropenem in clinical strains of Pseudomonas aeruginosa and Acinetobacter spp].
    Sacha P; Wieczorek P; Jakoniuk P; Zórawski M
    Wiad Lek; 2008; 61(1-3):30-6. PubMed ID: 18717040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro antibacterial activity and beta-lactamase stability of meropenem].
    Poiată A; Tuchiluş C; Bădicuţ I; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(3):589-94. PubMed ID: 14756067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Enterobacteriaceae, Pseudomonas and Acinetobacter in Southern Poland.
    Drzewiecki A; Bulanda M; Talaga K; Sodo A; Adamski P
    Pol Przegl Chir; 2012 Sep; 84(9):449-53. PubMed ID: 23241660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging resistance to carbapenems in a tertiary care hospital in north India.
    Gupta E; Mohanty S; Sood S; Dhawan B; Das BK; Kapil A
    Indian J Med Res; 2006 Jul; 124(1):95-8. PubMed ID: 16926463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
    Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
    Wiedemann B; Zühlsdorf M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of biapenem against beta-lactamase producing Enterobacteriaceae.
    Alonso R; Fernández-Aranguiz A; Colom K; Morla A; Suinaga E; Umaran A; Cisterna R
    Eur J Clin Microbiol Infect Dis; 1994 Oct; 13(10):820-2. PubMed ID: 7889951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
    Livermore DM; Yang YJ
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases.
    Yang Y; Bhachech N; Bush K
    J Antimicrob Chemother; 1995 Jan; 35(1):75-84. PubMed ID: 7768785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH).
    Lim CL; Lee W; Lee AL; Liew LT; Nah SC; Wan CN; Chlebicki MP; Kwa AL
    BMC Infect Dis; 2013 Nov; 13():523. PubMed ID: 24195651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.